Primary regulatory
Zadaxin (thymosin alpha-1) Product Information
SciClone Pharmaceuticals product information for Zadaxin (thymosin alpha-1), approved in over 30 countries for chronic hepatitis B, hepatitis C, and immune adjuvant use. Not FDA-approved in the United States.
SciClone PharmaceuticalsPublished Jul 1, 2026Accessed Jul 1, 2026
Registry record
Source metadata
- Publisher
- SciClone Pharmaceuticals
- Source type
- Primary regulatory
- Registry ID
sciclone-zadaxin-product-info
Source usage
Linked from 6 pages
Compound
Thymosin Alpha-1
Evidence curationBest Peptides for Immune Support
Evidence curationBest Peptides for Inflammation Research
GuideFDA Enforcement Timeline: Major Actions on Peptides and Compounding
GuidePeptide Category Explainers: How Every Compound Class on This Site Is Defined
GuidePeptide Half-Life Reference Table
Interpretation boundary
What this record can and cannot establish
Inclusion in the registry is not endorsement. The record supports only the claims that fit its design, population, date, and scope. Company, media, and community records can document that a claim was made without proving the claim itself.